These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

370 related items for PubMed ID: 14983507

  • 1. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
    Ren-Heidenreich L, Davol PA, Kouttab NM, Elfenbein GJ, Lum LG.
    Cancer; 2004 Mar 01; 100(5):1095-103. PubMed ID: 14983507
    [Abstract] [Full Text] [Related]

  • 2. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG.
    Clin Cancer Res; 2006 Jan 01; 12(1):183-90. PubMed ID: 16397041
    [Abstract] [Full Text] [Related]

  • 3. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG.
    Clin Cancer Res; 2006 Jan 15; 12(2):569-76. PubMed ID: 16428502
    [Abstract] [Full Text] [Related]

  • 4. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE, Miller M, Davol PA, Grabert RC, Davis JB, Lum LG.
    Anticancer Res; 2005 Jan 15; 25(1A):43-52. PubMed ID: 15816517
    [Abstract] [Full Text] [Related]

  • 5. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
    Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, Kiener PA.
    Cancer Res; 2007 Apr 15; 67(8):3927-35. PubMed ID: 17440108
    [Abstract] [Full Text] [Related]

  • 6. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, Lum LG, Negrin RS.
    Clin Cancer Res; 2006 Mar 15; 12(6):1859-67. PubMed ID: 16551871
    [Abstract] [Full Text] [Related]

  • 7. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM, Davol PA, Grabert RC, Deaver M, Lum LG.
    Exp Hematol; 2005 Apr 15; 33(4):452-9. PubMed ID: 15781336
    [Abstract] [Full Text] [Related]

  • 8. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C, Kornacker M, Scheffold YC, Contag CH, Negrin RS.
    Cancer Res; 2002 Oct 15; 62(20):5785-91. PubMed ID: 12384539
    [Abstract] [Full Text] [Related]

  • 9. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A, Mezzanzanica D, Jung G, Wolf H, Colnaghi MI, Canevari S.
    Cancer Res; 1996 Dec 01; 56(23):5443-9. PubMed ID: 8968099
    [Abstract] [Full Text] [Related]

  • 10. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, Tso JY, Waldmann TA.
    Cancer Res; 2000 Dec 15; 60(24):6977-84. PubMed ID: 11156399
    [Abstract] [Full Text] [Related]

  • 11. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsässer-Beile U.
    Anticancer Res; 2000 Dec 15; 20(3A):1551-5. PubMed ID: 10928069
    [Abstract] [Full Text] [Related]

  • 12. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI, Nelson H, Thibault C.
    J Immunol; 1995 Aug 01; 155(3):1296-303. PubMed ID: 7636196
    [Abstract] [Full Text] [Related]

  • 13. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I, Holmes M, Gercel-Taylor C, Weiner LM.
    Cancer Res; 1992 Oct 15; 52(20):5713-9. PubMed ID: 1394194
    [Abstract] [Full Text] [Related]

  • 14. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
    Zhou J, Chen J, Zhong R, Mokotoff M, Shultz LD, Ball ED.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2224-31. PubMed ID: 16609038
    [Abstract] [Full Text] [Related]

  • 15. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
    Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P, Wimberger P, Kimmig R, Fichtner I, Kufer P, Hofmeister R, da Silva AJ, Baeuerle PA.
    Mol Immunol; 2006 Mar 01; 43(8):1129-43. PubMed ID: 16139892
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapy with bispecific antibodies.
    Thielemans KM.
    Verh K Acad Geneeskd Belg; 1995 Mar 01; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [Abstract] [Full Text] [Related]

  • 17. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
    Bortoletto N, Scotet E, Myamoto Y, D'Oro U, Lanzavecchia A.
    Eur J Immunol; 2002 Nov 01; 32(11):3102-7. PubMed ID: 12385030
    [Abstract] [Full Text] [Related]

  • 18. Bispecific antibody-mediated lysis of placental and germ cell alkaline phosphatase targeted solid tumors in immunocompetent mice.
    Smans KA, Hoylaerts MF, Narisawa S, Millán JL, De Broe ME.
    Cancer Res; 1995 Oct 01; 55(19):4383-90. PubMed ID: 7671251
    [Abstract] [Full Text] [Related]

  • 19. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R, Raum T, Kischel R, Lutterbuese P, Schlereth B, Schaller E, Mangold S, Rau D, Meier P, Kiener PA, Mulgrew K, Oberst MD, Hammond SA, Baeuerle PA, Kufer P.
    J Immunother; 2009 May 01; 32(4):341-52. PubMed ID: 19342971
    [Abstract] [Full Text] [Related]

  • 20. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G, Gückel B, Wallwiener D, Moldenhauer G.
    Clin Cancer Res; 1999 Jan 01; 5(1):171-80. PubMed ID: 9918216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.